Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DV-CAG regimen in T-cell acute lymphoblastic leukemia (real-world study)
ChiCTR2500110926Phase 3Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Oct 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of daratumumab, venetoclax, cytarabine, granulocyte colony-stimulating factor and aclarubicin in acute lymphoblastic leukemia (ALL), sponsored by Ruijin Hospital. Primary endpoint: ratio of negative minimal residual disease. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
daratumumabvenetoclaxcytarabinegranulocyte colony-stimulating factoraclarubicin
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on ChiCTR2500110926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500110926.